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Myeloid-derived suppressor cells (MDSCs) are a hetero-
geneous group of cells with potent immune suppressive
activity in cancer and many other pathologic conditions.
MDSCs consist of two major subsets: monocytic
MDSCs (M-MDSCs) and polymorphonuclear MDSCs
(PMN-MDSCs). Each subset of MDSCs is thought
to be developed through the separate differentiation
pathways. Here, we demonstrated that in a tumor
environment a large proportion of M-MDSCs acquired
phenotypic, morphological and functional features
of PMN-MDSCs while the normal counterpart of
M-MDSCs-Ly6ChiLy6G- inflammatory monocytes (Mon)
from tumor-free mice differentiate to macrophages (MF)
and dendritic cells (DCs). This process was mediated by
loss of the retinoblastoma (Rb1) protein in MDSCs. Inhibi-
tion of Rb1 expression in PMN-MDSCs correlated with
the level of histone acetylation of Rb1 promoter. Treat-
ment of PMN-MDSCs with inhibitors of histone deacety-
lases (HDAC) resulted in the increase in Rb1 expression.
In addition, inhibition of HDAC abrogated differentiation
of M-MDSCs to PMN-MDSCs, and restored M-MDSCs
differentiation towards DCs and MF. These results
suggest that down-regulation of Rb1 by epigenetic modi-
fication plays a major role in expansion of MDSCs in can-
cer by regulating PMN-MDSCs differentiation from
M-MDSCs. Therefore, inhibition of MDSCs accumulation
by treatment of HDAC inhibitors may be considered as a
potential therapeutic tool in cancer immunotherapy.
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